David L. Ebel

1.4k citations

27 papers · 1.1k indexed · h-index 13

Impact in

Pharmacology top 2%
- Inflammatory mediators and NSAID effects
- Pharmacogenetics and Drug Metabolism
- Drug-Induced Adverse Reactions
Biochemistry top 2%
- Eicosanoids and Hypertension Pharmacology

Papers in

Pharmacology 8
- Inflammatory mediators and NSAID effects 11
- Pharmacogenetics and Drug Metabolism 8
- Pharmacology and Obesity Treatment 3
Biochemistry 5
- Eicosanoids and Hypertension Pharmacology 5

Co-authors: Jules I. Schwartz Barry J. Gertz Inge De Lepeleire P.J. De Schepper Anne Van Hecken Kenneth C. Lasseter Stacy C. Dilzer Aimée Dallob
Journals: The Journal of Clinical Pharmacology (9 papers)Biopharmaceutics & Drug Disposition (2 papers)Clinical Pharmacology & Therapeutics (2 papers)The Journal of Clinical Endocrinology & Metabolism (2 papers)Annals of Internal Medicine (1 paper)
Partner nations: United States Belgium Germany

In The Last Decade

David L. Ebel

26 papers receiving 999 citations

Peers

Countries citing papers authored by David L. Ebel

Since Specialization

Citations

This map shows the geographic impact of David L. Ebel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Ebel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Ebel more than expected).

Fields of papers citing papers by David L. Ebel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Ebel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Ebel. The network helps show where David L. Ebel may publish in the future.

Co-authors

The 25 scholars most cited alongside David L. Ebel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David L. Ebel Line = papers co-authored together David L. Ebel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D₂ Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers The Journal of Clinical Pharmacology ·Wen‐Lin Luo, Tami Crumley, David L. Ebel, George Atiee, Jane Royalty, Amy O. Johnson‐Levonas, John A. Wagner, Eseng Lai	2010	2
2	Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers Current Therapeutic Research ·Samuel S. Dychter, David L. Ebel, Yunia Makin Aninda Fiqrotin Nisa', Richard C. Yocum	2009	13
3	Effects of Aspirin When Added to the Prostaglandin D₂ Receptor Antagonist Laropiprant on Niacin‐Induced Flushing Symptoms The Journal of Clinical Pharmacology ·Victor Dishy, Fang Liu, David L. Ebel, George Atiee, Jane Royalty, Florian Urs Bernlochner, John F. Paolini, John A. Wagner, Eseng Lai	2009	16
4	Lack of Effect of Antacids on Single‐Dose Pharmacokinetics of Etoricoxib The Journal of Clinical Pharmacology ·Jules I. Schwartz, Nancy Agrawal, Uma Kher, L. Blakee, Paul F. Cavanaugh, Michel Guillaume, David L. Ebel, Hao-Jen You, John A. Wagner	2007	9
5	Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans Drug Metabolism and Disposition ·Stella Vincent, James R. Reed, Arthur Bergman, Charles S. Elmore, Bing Zhu, Shiyao Xu, David L. Ebel, Patrick Larson, Wei Zeng, Li Chen, Stacy C. Dilzer, Kenneth C. Lasseter, Keith Gottesdiener, John A. Wagner, Gary Herman	2007	127
6	Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers Biopharmaceutics & Drug Disposition ·Arthur Bergman, David L. Ebel, Fang Liu, Julie A. Stone, Amy Wang, Wei Zeng, Li Chen, Stacy C. Dilzer, Kenneth C. Lasseter, Gary Herman, John A. Wagner, Rajesh Krishna	2007	70
7	Effect of Rofecoxib on Prednisolone and Prednisone Pharmacokinetics in Healthy Subjects The Journal of Clinical Pharmacology ·Jules I. Schwartz, Saurabh Mukhopadhyay, Arturo G. Porras, Greg Marchetti, Luo Yan-hon, David L. Ebel, Barry J. Gertz	2003	2
8	Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, a potent, highly selective PDE-5 inhibitor for the treatment of erectile dysfunction Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Jules I. Schwartz, Arturo G. Porras, Peggy H. Wong, Anne Van Hecken, Tomalá Chavarría, Icela Beltrán-Hernández, Thomas R. Hunt, David L. Ebel, Betty Ann Heliums, Yutaka Kikuchi, B. J. Gertz, Fazilah A. Latif	2002	0
9	Effect of Rofecoxib on the Pharmacokinetics of Chronically Administered Oral Contraceptives in Healthy Female Volunteers The Journal of Clinical Pharmacology ·Jules I. Schwartz, Peggy H. Wong, Arturo G. Porras, David L. Ebel, Thomas R. Hunt, Barry J. Gertz	2002	6
10	THE COX-2 INHIBITOR ETORICOXIB DID NOT ALTER THE ANTI-PLATELET EFFECTS OF LOW-DOSE ASPIRIN IN HEALTHY VOLUNTEERS. Arthritis & Rheumatism ·John A. Wagner, Walter K. Kraft, Joanne Burke, Peggy Wong, Inigo Johnson, Evanilza Lopes de Castro Paes, David L. Ebel, Jyotirmay Gadedadikar, Keith Gottesdiener, Scott A. Waldman, Howard Greenberg	2001	5
11	Lack of Pharmacokinetic Interaction between Rofecoxib and Methotrexate in Rheumatoid Arthritis Patients The Journal of Clinical Pharmacology ·Jules I. Schwartz, Nancy Agrawal, Peggy H. Wong, Kenneth Bachmann, Arturo G. Porras, Jutta Miller, David L. Ebel, Marshall Sack, Gregory B. Holmes, Jan S. Redfern, Barry J. Gertz	2001	26
12	Effect of Rofecoxib on the Pharmacokinetics of Digoxin in Healthy Volunteers The Journal of Clinical Pharmacology ·Jules I. Schwartz, Marina De Smet, Ahmad Alfan Fauzi, René Verbesselt, David L. Ebel, R. Lins, B Wang, Arturo G. Porras, Barry J. Gertz	2001	12
13	In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics Pharmacogenetics ·Cuyue Tang, Magang Shou, Thomas H. Rushmore, Mei Qin, Punam Sandhu, Eric Woolf, Mark J. Rose, J. Postell, Howard Greenberg, Inge De Lepeleire, Anne Van Hecken, P.J. De Schepper, David L. Ebel, Jules I. Schwartz, A. David Rodrigues	2001	96
14	Effect of Montelukast on Single-Dose Theophylline Pharmacokinetics American Journal of Therapeutics ·Kerstin Malmström, Jules I. Schwartz, Theodore F. Reiss, Timothy J. Sullivan, James H. Reese, Luis Jáuregui, 真智子西尾, José Hakim-Tawil, Sumiko Shingo, 長倉のり子, Patrick Larson, David L. Ebel, Thomas L. Hunt, Richard D. Huhn, Kenneth Bachmann	1998	15
15	MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen¹ The Journal of Clinical Endocrinology & Metabolism ·Jules I. Schwartz, Wesley Tanaka, Queen Mwaipopo, David L. Ebel, Shane Weiner, Aimée Dallob, Barry Hafkin, Barry J. Gertz	1997	30
16	MK-386, an Inhibitor of 5 alpha-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum Without Affecting Dihydrotestosterone Concentrations in Semen Obstetrical & Gynecological Survey ·Jules I. Schwartz, Wesley Tanaka, Queen Mwaipopo, David L. Ebel, Shane Weiner, Aimée Dallob, Barry Hafkin, Barry J. Gertz	1997	9
17	Novel Oral Medication Delivery System for Famotidine The Journal of Clinical Pharmacology ·Jules I. Schwartz, K. C. Yeh, Marc L. Berger, Lisa Tomasko, I.D. Laktaev, David L. Ebel, Katya Salkever, Tran Truong, Thorir D. Bjornsson	1995	10
18	The bioavailability and nonlinear pharmacokinetics of MK‐679 in humans Biopharmaceutics & Drug Disposition ·Haiyung Cheng, Jules I. Schwartz, Charles C. Lin, Raju D. Amin, James R. Seibold, Kenneth C. Lasseter, David L. Ebel, Dominick J. Tocco, John Rogers	1994	2
19	Evaluation of Sustained/Controlled-Release Dosage Forms of 3-Hydroxy-3-methylglutaryl–Coenzyme A (HMG-CoA) Reductase Inhibitors in Dogs and Humans Pharmaceutical Research ·Haiyung Cheng, Steven C. Sutton, J.D. Pipkin, Gaylen M. Zentner, John Rogers, Jules I. Schwartz, M. Noack, Kenneth Grasing, Michael S. Schwartz, Raju D. Amin, Lida Liu, David L. Ebel, A.W. Coulter, Karen Engle, J.H. Liu, Chung Y. Lui, Gerald S. Rork	1993	27
20	A multi-centre, double-blind randomized study to assess the efficacy and tolerance of sulindac versus placebo in the symptomatic treatment of patients with upper respiratory tract infection Current Medical Research and Opinion ·David L. Ebel, Weichung Joe Shih, Ar-Rahman Llewellyn	1985	8

About David L. Ebel

David L. Ebel is a scholar working on Pharmacology, Pharmacology, Biochemistry, Endocrinology, Diabetes and Metabolism and Toxicology, having authored 27 papers that have together received 1.1k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (11 papers), Pharmacogenetics and Drug Metabolism (8 papers), Eicosanoids and Hypertension Pharmacology (5 papers), Hormonal and reproductive studies (4 papers), Pharmacology and Obesity Treatment (3 papers), Sexual Differentiation and Disorders (3 papers), Drug Transport and Resistance Mechanisms (2 papers) and Respiratory and Cough-Related Research (2 papers). The work is most often cited by research in Pharmacology (547 citations), Biochemistry (182 citations), Pharmacology (218 citations), Endocrinology, Diabetes and Metabolism (238 citations) and Cardiology and Cardiovascular Medicine (172 citations). David L. Ebel has collaborated with scholars based in United States, Belgium and Germany. Frequent co-authors include Jules I. Schwartz, Barry J. Gertz, Inge De Lepeleire, P.J. De Schepper, Anne Van Hecken, Kenneth C. Lasseter, Stacy C. Dilzer, Aimée Dallob, Wesley Tanaka and Peggy H. Wong. Their work appears in journals such as The Journal of Clinical Pharmacology, Biopharmaceutics & Drug Disposition, Clinical Pharmacology & Therapeutics, The Journal of Clinical Endocrinology & Metabolism and Annals of Internal Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact